Serious Injuries Prompt New FDA Labeling Recommendations For Dermal Fillers
This article was originally published in The Gray Sheet
Executive Summary
FDA urged dermal filler firms to update labeling to warn of rare but serious complications that can occur when the soft tissue products are unintentionally injected into facial blood vessels in conjunction with a safety communication to providers and patients on the topic.